Long-acting beta-agonists and inhaled corticosteroids for treatment of chronic obstructive pulmonary disease: a review of the clinical efficacy and cost-effectiveness
CADTH
Record ID 32014000163
English
Authors' recommendations:
Compared with tiotropium monotherapy, adding formoterol to tiotropium statistically significantly improved the lung function (FEV1) in the treatment of patients with moderate to severe COPD; Adding budesonide/formoterol to tiotropium statistically significantly improved lung function (FEV1) and reduced the frequency of severe exacerbation, and appears cost effective compared with tiotropium monotherapy in the treatment of severe COPD. The long term comparative clinical effectiveness, harms and the cost effectiveness of these COPD treatment strategies remain to be established.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/may-2013/RC0446%20COPD%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Pulmonary Disease, Chronic Obstructive
- Adrenergic beta-Agonists
- Bronchodilator Agents
- Corticosterone
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.